Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, May 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Medivation, Inc. (NASDAQ: MDVN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Boston Scientific Corporation (NYSE: BSX), Danaher Corp. (NYSE: DHR) and Caterpillar Inc. (NYSE: CAT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2433-100free.
Medivation, Inc. Analyst Notes
On May 8, 2014, Medivation, Inc. (Medivation) reported Q1 2014 earnings. Medivation reported collaboration revenue during the quarter increased 88.9% YoY to $87.2 million, but fell short of the Zacks' consensus estimates of $112.0 million. The Company informed that U.S. sales of XTANDI (enzalutamide) capsules were $124.5 million. Medivation and Astellas Pharma Inc. ("Astellas") are jointly responsible for commercialization and development of XTANDI in the U.S. and share equally in the costs, profits and losses arising from this drug in U.S. During the quarter, Medivation narrowed down its net loss to $13.7 million, or $0.18 per diluted share, from a net loss of $27.2 million, or $0.36 per diluted share, for Q1 2013. However, the net loss was wider than the Zacks consensus estimate of a loss of $0.03 per share. For 2014, Medivation expects U.S. net sales of XTANDI to be in the range of $540 - $575 million. The full analyst notes on Medivation are available to download free of charge at:
Alexion Pharmaceuticals, Inc. Analyst Notes
On May 5, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab). The Company informed that Soliris is indicated for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). The development reflects Alexion's fulfillment of post-marketing requirements, including the submission of confirmatory data from two additional prospective clinical trials, including one in pediatric patients with aHUS. Commenting on the development, Leonard Bell, CEO, Alexion said "We are pleased that, since 2011, the FDA's Accelerated Approval process has enabled us to provide Soliris to individuals whose lives have been at risk of the severe clinical manifestations of aHUS and who would otherwise have had no safe or effective treatment options." The full analyst notes on Alexion are available to download free of charge at:
Boston Scientific Corporation Analyst Notes
On May 10, 2014, Boston Scientific Corporation (Boston Scientific) issued a press release announcing results of the PREDICt-RM study (Patient RElated Determinants of ICD Remote Monitoring Utilization and Outcomes) - a collaborative study between Boston Scientific, American College of Cardiology and Yale University. According to the study results, patients using Boston Scientific LATITUDE™ Remote Patient Management system with wireless telemetry demonstrated significantly lower mortality and fewer hospitalizations than patients with LATITUDE-compatible devices who were not followed on the system. Commenting on the development, Kenneth Stein, M.D., Chief Medical Officer, Rhythm Management, Boston Scientific, said "PREDICt-RM demonstrates that wireless remote monitoring using the LATITUDE system provides a significant benefit to patients and the overall healthcare system. We are very excited to have such strong data demonstrating substantially improved survival and reduced hospitalization rates in the patients followed on LATITUDE." The full analyst notes on Boston Scientific are available to download free of charge at:
Danaher Corp. Analyst Notes
On May 6, 2014, Danaher Corp. (Danaher) announced that its Board of Directors has approved a regular quarterly dividend of $0.10 per share payable on July 25, 2014 to holders of record on June 27, 2014. Danaher designs, manufactures and markets professional, medical, industrial and commercial products and services. The full analyst notes on Danaher are available to download free of charge at:
Caterpillar Inc. Analyst Notes
On May 5, 2014, Wall Street Journal (WSJ) reported that Caterpillar Inc. (Caterpillar) sold 50-year bonds, the first such long-dated bond issuance by any U.S. company (excluding financial institutions) in nearly a year. The 50-year corporate bonds were issued as part of a Caterpillar's $2 billion debt sale. According to the report, the Company sold $500 million of 50-year bonds due 2064, yielding 1.375 percentage points more than Treasuries. WSJ further reported that the Company also sold 10-year and 30-year debt, to yield 0.80 and 0.95 percentage point over Treasuries. The full analyst notes on Caterpillar are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.